pad-1 Antibody

Biochemical Characteristics of PAD1 Antibody

Target Enzyme:
PAD1 (Peptidylarginine Deiminase 1) catalyzes the conversion of arginine residues to citrulline in proteins, a process implicated in epidermal differentiation and pathological conditions like rheumatoid arthritis (RA) .

Antibody Types:

• Monoclonal Antibodies: High specificity for human PAD1, validated for Western blot (WB) and immunohistochemistry (IHC) .

• Polyclonal Antibodies: Detect PAD1 across species (human, mouse, rat) with applications in ELISA, IHC, and immunocytochemistry (ICC) .

Key Epitopes:
Antibodies such as ab251967 target recombinant fragments of human PAD1 (amino acids 450–550), enabling precise localization in cellular studies .

Diagnostic Performance in Rheumatoid Arthritis

Anti-PAD1 antibodies demonstrate significant diagnostic potential, particularly in seronegative RA patients (ACPA-negative):

Data derived from ROC analysis of 532 RA patients and 270 controls .

• Clinical Utility: The composite score of anti-PAD1/4 improves RA diagnosis sensitivity by 12% in ACPA-negative cases compared to individual markers .

Research Applications

Table 1: Common Applications of PAD1 Antibodies

Role in Triple-Negative Breast Cancer (TNBC)

• Mechanism: PAD1 promotes epithelial-mesenchymal transition (EMT) by upregulating MMP2/9, facilitating metastasis in MDA-MB-231 cells .

• Therapeutic Target: PAD1 inhibition reduces tumor proliferation by 40% in xenograft models and suppresses ERK1/2 and P38 MAPK signaling pathways .

Limitations and Future Directions

• Current Gaps: Overlap between anti-PAD1 and anti-PAD4 antibodies in RA necessitates larger validation studies .

• Emerging Roles: PAD1’s involvement in non-autoimmune conditions (e.g., cancer) warrants exploration of isoform-specific inhibitors .